HC Wainwright & Co. Reiterates Buy on Armata Pharmaceuticals, Maintains $7 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Joseph Pantginis has reiterated a 'Buy' rating on Armata Pharmaceuticals (AMEX:ARMP) and maintained a $7 price target.
August 14, 2023 | 3:10 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated a 'Buy' rating on Armata Pharmaceuticals and maintained a $7 price target, potentially indicating positive sentiment towards the stock.
Analyst ratings and price targets can significantly influence investor sentiment and stock prices. The reiteration of a 'Buy' rating and maintenance of a $7 price target by HC Wainwright & Co. suggests they believe the stock is undervalued at current prices, which could lead to increased buying pressure and a potential increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100